Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del MutationBusiness Wire • 04/20/22
Vertex shares promising clinical data for its experimental non-opioid pain treatmentMarket Watch • 03/31/22
Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute PainBusiness Wire • 03/31/22